Population Council to present research on novel approaches to HIV prevention at HIV R4P 2014

The Population Council will present new research on novel approaches to HIV, sexually transmitted infections (STIs), and unintended pregnancy prevention at the HIV Research for Prevention Conference, (HIV R4P) in Cape Town, South Africa. HIV R4P, which runs 28–31 October, is the first global scientific meeting dedicated exclusively to research on biomedical HIV prevention.

Presentations by Council researchers include advances in the development of a microbicide/contraceptive intravaginal ring (IVR) to protect against HIV, HPV, herpes (HSV-2), and unintended pregnancy (oral abstract session 3, 28 October, 11:00 am–12:30 pm); the first-in-human safety and pharmacokinetics study of the Council's ARV-based microbicide gel, PC-1005 (poster session, 29 October, 10:00–11:00 am and 5:00–6:30 pm); and the activity of the non-ARV microbicide griffithsin against HSV-2 and human papillomavirus (HPV) (poster session, 30 October, 10:00–11:00 am and 5:00–6:30 pm).

Other Council studies on the HIV R4P agenda include new research on the connection between bacterial vaginosis and HSV-2 susceptibility (oral abstract session 10, 28 October, 1:30–3:00 pm); studies on the factors affecting the uptake of HIV counseling and testing among young people (poster session, 29 October, 10:00–11:00 am and 5:00–6:30 pm); and research on the links between counseling and testing and sexual risk behaviors (poster session, 29 October, 10:00–11:00 am and 5:00–6:30 pm).

Council scientists are also advancing global research on multi-purpose prevention technologies (MPTs), new tools in development that are designed to protect against HIV, STIs, and/or unintended pregnancy with a single product. The Council will co-chair a conference roundtable on the topic (31 October, 8:30–10:00 am), and will co-sponsor a satellite session at HIV R4P addressing the promise of MPTs in combination HIV and STI protection (31 October, 1:30–3:30 pm).

"HIV, STIs, and unintended pregnancy are global health crises that together affect hundreds of millions of women and men worldwide," said Naomi Rutenberg, Population Council vice president and director of the Council's HIV and AIDS program, and co-chair of the MPT roundtable on MPTs on 31 October at 8:30 am. "Council researchers are working on new approaches to these critical sexual health challenges that are safe, effective, easier to use, and responsive to the needs and life circumstances of the people they are designed to help."

"Sexually active people are often at simultaneous risk for HIV, STIs that can increase their risk of HIV, and unintended pregnancy," noted Tom Zydowsky, who leads the Council's pharmaceutical development program in HIV and AIDS. "The Council's work to advance MPTs is based in our belief that better and more convenient options are needed to slow these interconnected global epidemics and help women and men to lead healthier lives."

Presentations by Council researchers at HIV R4P are listed below:

TUESDAY, 28 OCTOBER

Oral Sessions

A novel intravaginal ring (IVR) protects macaques against SHIV-RT infection and reduces HSV-2 shedding after repeated SHIV-RT/HSV-2 co-challenge

11:00 am–12:30 pm, Auditorium 2

Presenter: Thomas M. Zydowsky

HSV-2-driven changes in α4β7 expression correlate with increased susceptibility to SHIV ex vivo and in vivo

1:30–3:00 pm, Roof Terrace Room

Presenter: Elena Martinelli

WEDNESDAY, 29 OCTOBER

Poster Sessions

Socio-demographic factors associated with uptake of HIV counseling and testing (HCT) among Nigerian youth

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Ayodeji Oginni

Does HIV counseling and testing change sexual risk behaviors? Findings from a community health center (CHC) in North Central Nigeria

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Ibrahim Suleiman

ARV-based prevention for women: New data on HIV testing behaviors from potential users of vaginal microbicides in Mpumalanga, South Africa

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Martha Brady

Are Nigerian healthcare providers (HCP) prepared for men who have sex with men (MSM): Lessons from the mystery client survey in Nigeria

The anti-same sex marriage law implications on HIV interventions for men who have sex with men in Nigeria

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Chiedu Ifekandu

MZC and 1% TFV gel: Multipurpose prevention approaches

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: José Fernández-Romero

First-in-human safety and pharmacokinetics (PK) of a MIV-150/zinc acetate/carrageenan gel (PC-1005)

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: George W. Creasy

THURSDAY, 30 OCTOBER

Poster Sessions

Antiviral activity and mode of action of griffithsin against HSV-2 and HPV: Preliminary studies of a potential non-ARV combination microbicide

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: José Fernández Romero

Reporting of adherence in the VOICE trial: Does disclosure of product non-use increase at the termination visit?

Reporting of challenges to adherence in VOICE: A comparison of quantitative and qualitative self-reports among women during and after the trial

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Barbara Mensch

Patterns of drug use among people who inject drugs (PWID) and their implications for sexually transmitted infections in northern Nigeria

10:00–11:00 am, 5:00–6:30 pm, Hall 2

Presenter: Desmond Iriaye

FRIDAY, 31 OCTOBER

Roundtable

Multipurpose Technologies

8:30–10:00 am, Meeting Room 1.60

Co-chairs: Naomi Rutenberg, Population Council; Manjula Lusti-Narasimhan, WHO

Panel: Judy Manning, Joseph Romano, Charu Mullick, Elizabeth Brown, and Elizabeth Bukusi

Satellite Session

Multi-Purpose Prevention Technologies (MPTs): The Future of HIV and STI Protection?

1:30–3:30 pm, Meeting Room 1.61–1.62

Co-chairs: José Fernández Romero, Population Council; Manjula Lusti-Narasimhan, WHO

Panel: Carolyn Deal, Betsy Herold, Dorothy Patton, Joe Romano, John Schiller, Tom Zydowsky

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New hepatitis B vaccine offers superior protection for people with HIV